Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: A systematic review

Blood

Volumn 122, Issue 5, 2013, Pages 817-824

  Garcia, David ^a   Akl, Elie A ^b,c,d   Carr, Richard ^e   Kearon, Clive ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY AT BUFFALO   (United States)

^e UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CARDIOLIPIN ANTIBODY; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; XIMELAGATRAN;

ANTICOAGULANT THERAPY; ARTICLE; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; FOLLOW UP; HUMAN; LUNG EMBOLISM; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; RISK FACTOR; SYSTEMATIC REVIEW; VENOUS THROMBOEMBOLISM; ALGORITHM; ANIMAL; BLOOD; COHORT ANALYSIS; PATHOLOGY; PHYSIOLOGY; RECURRENT DISEASE; REVIEW;

ALGORITHMS; ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; COHORT STUDIES; FOLLOW-UP STUDIES; HUMANS; RECURRENCE; RISK FACTORS; VENOUS THROMBOEMBOLISM;

EID: 84886379226     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-04-496257     Document Type: Article

References (24)

1. de Groot P.G., Derksen RH. Pathophysiology of the antiphospholipid syndrome. J Thromb Haemost. 2005; 3(8): 1854-1860. (Pubitemid 41716572)
2. Shi W, Krilis SA, Chong B.H., Gordon S., Chesterman CN. Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population. Aust N Z J Med. 1990; 20(3): 231-236. (Pubitemid 20283041)
3. Vila P, Hernández MC, López-Fernández MF, Batlle J. Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. Thromb Haemost. 1994; 72(2): 209-213. (Pubitemid 24251281)
4. Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective. Scand J Rheumatol. 1996; 25(4): 191-193. (Pubitemid 26273848)
5. Pengo V, Ruffatti A, Legnani C., et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood. 2011; 118(17): 4714-4718.
6. Opatrny L, David M, Kahn S.R., Shrier I., Rey E. Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a metaanalysis. J Rheumatol. 2006; 33(11): 2214-2221. (Pubitemid 44749780)
7. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006; 4(2): 295-306.
8. Ginsberg JS, Wells PS, Brill-Edwards P, et al. Antiphospholipid antibodies and venous thromboembolism. Blood. 1995; 86(10): 3685-3691.
9. Roldan V, Lecumberri R, Muñoz-Torrero JF, Vicente V, Rocha E, Brenner B, et al; RIETE Investigators. Thrombophilia testing in patients with venous thromboembolism. Findings from the RIETE registry. Thromb Res. 2009; 124(2): 174-177.
10. Ruiz-Irastorza G., Cuadrado MJ, Ruiz-Arruza I, et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus. 2011; 20(2): 206-218.
11. Derksen RH, de Groot PG, Kater L, Nieuwenhuis HK. Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment. Ann Rheum Dis. 1993; 52(9): 689-692. (Pubitemid 23280441)
12. Garcia DA, Khamashta MA, Crowther MA. How we diagnose and treat thrombotic manifestations of the antiphospholipid syndrome: a case-based review. Blood. 2007; 110(9): 3122-3127. (Pubitemid 350106302)
13. Hayden JA, van der Windt DA, Cartwright JL, Côté P, Bombardier C. Assessing bias in studies of prognostic factors. Ann Intern Med. 2013; 158(4): 280-286.
14. Taliani MR, Becattini C, Agnelli G., et al.; Warfarin Optimal Duration Italian Trial (WODIT) Investigators. Duration of anticoagulant treatment and recurrence of venous thromboembolism in patients with and without thrombophilic abnormalities. Thromb Haemost. 2009; 101(3): 596-598.
15. Bank I, Tick LW, Hutten B.A., Kramer MH, Middeldorp S, Büller HR. Acquired and inherited thrombophilic factors and the risk for residual venous thrombosis. Pathophysiol Haemost Thromb. 2003; 33(4): 192-196. (Pubitemid 39664137)
16. Kearon C, Gent M, Hirsh J., et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med. 1999; 340(12): 901-907. (Pubitemid 29141050)
17. Kearon C, Ginsberg JS, Anderson D.R., et al.; SOFAST Investigators. Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor. J Thromb Haemost. 2004; 2(5): 743-749. (Pubitemid 40192487)
18. Rodger MA, Kahn SR, Wells P.S., et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ. 2008; 179(5): 417-426.
19. Wåhlander K., Eriksson H, Lundström T, et al.; THRIVE III Investigators. Risk of recurrent venous thromboembolism or bleeding in relation to thrombophilic risk factors in patients receiving ximelagatran or placebo for long-term secondary prevention of venous thromboembolism. Br J Haematol. 2006; 133(1): 68-77. (Pubitemid 43327200)
20. Schulman S, Lindmarker P, Holmström M, et al. Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost. 2006; 4(4): 734-742.
21. Agnelli G, Prandoni P, Becattini C., et al.; Warfarin Optimal Duration Italian Trial Investigators. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med. 2003; 139(1): 19-25.
22. Agnelli G, Prandoni P, Santamaria M.G., et al.; Warfarin Optimal Duration Italian Trial Investigators. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Engl J Med. 2001; 345(3): 165-169. (Pubitemid 32662124)
23. Galli M, Luciani D, Bertolini G., Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003; 101(5): 1827-1832. (Pubitemid 36237580)
24. Kearon C, Akl EA, Comerota A.J., et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl): e419S-494S.